TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01062893

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline 0 mls
Description: at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15 mls sterile normal saline
Description: After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
Study: NCT03975257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device: Ectoin Lozenge
Description: Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
Study: NCT03880253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Placebo or CTP-692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Placebo or CTP-692
Study: NCT01820520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brilliant blue G
Description: Double staining with brilliant blue G 0.025% for macular surgery
Study: NCT03231124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: LEO 32731 is being developed by LEO Pharma.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration, only lacking LEO 32731
Study: NCT00581893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT03270410

Intervention type: OTHER
Intervention: Data collection
Description: After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care.
Study: NCT01848613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study: NCT04220398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with hormone therapy
Description: Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant hormone therapy
Description: HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy (RP)+ extended lymph node dissection
Description: Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy (RP)+ extended lymph node dissection
Description: Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical Prostatectomy (RP)+ extended lymph node dissection
Description: Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery.
Study: NCT01504776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT03235700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal hyperemia with adenosine followed by nicorandil
Description: IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal hyperemia with nicorandil followed by adenosine
Description: IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
Study: NCT02550938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign
Description: The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign
Description: The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign
Description: The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign
Description: The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
Study: NCT00953771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
Study: NCT03063151

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Surface Electromyography (EMG)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Surface Electromyography (EMG)
Study: NCT02224404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Gelling Dressing (Exufiber)
Study: NCT00660322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Asthma Program
Description: The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~1. Using asthma controller medications as prescribed~2. Having and Asthma Action Plan available to all who may need it.~3. Using asthma rescue medications with the child's first symptoms.~4. Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year.
Study: NCT03085836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets.
Study: NCT03274115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLI (Blue Laser Imaging)
Description: Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
Study: NCT04491877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine formulation 1
Description: Pharmaceutical form: Suspension of virus Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine formulation 1
Description: Pharmaceutical form: Suspension of virus Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine formulation 1
Description: Pharmaceutical form: Suspension of virus Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine formulation 2
Description: Pharmaceutical form: Suspension of virus Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine formulation 2
Description: Pharmaceutical form: Suspension of virus Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Suspension Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Suspension Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Suspension Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Suspension Route of administration: Intranasal
Study: NCT02084758

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate supplementation
Description: 7 days of supplementation with sodium nitrate solution

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate supplementation
Description: 7 days of supplementation with sodium nitrate solution

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo supplementation
Description: 7 days of supplementation with sodium chloride solution

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: 7 days of supplementation with sodium chloride solution
Study: NCT04127981

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET + Dexa Scan
Description: 18F-FDG PET will be compared with Dexa Scan result within and between arms.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET + Dexa Scan
Description: 18F-FDG PET will be compared with Dexa Scan result within and between arms.
Study: NCT03620539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Sauna bathing
Study: NCT02436291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURE-EX device
Description: Treatment with CURE-EX device twice daily for 24-30 weeks.
Study: NCT01857375

Intervention type: DEVICE
Intervention: Insulin Pen Device
Description: Insulin pen was compared to administration of insulin using standard syringes.
Study: NCT00688129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KITS Program
Description: This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
Study: NCT00876824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B Lipid emulsion
Description: Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
Study: NCT02912390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cerclage
Description: Macdonald cerclage placed in standard fashion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant management
Description: placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
Study: NCT04267965

Intervention type: PROCEDURE
Intervention: parathyroidectomy plus bilateral thymectomy and autotransplantation
Description: Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
Study: NCT03459872

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Alternative medicine therapeutic intervention

Intervention type: DEVICE
Intervention: RU-Fit
Description: FDA approved medical device for the measurement of fine motor control

Intervention type: DEVICE
Intervention: RU-Fit
Description: FDA approved medical device for the measurement of fine motor control
Study: NCT00954889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: (tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
Study: NCT05959798

Intervention type: PROCEDURE
Intervention: High power short duration ablation
Description: Pulmonary vein isolation by high power short duration radiofrequency catheter ablation

Intervention type: PROCEDURE
Intervention: High power short duration ablation
Description: Pulmonary vein isolation by high power short duration radiofrequency catheter ablation
Study: NCT04756076

Intervention type: DIAGNOSTIC_TEST
Intervention: Metal level measurements
Description: Measure multiple metal levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Metal level measurements
Description: Measure multiple metal levels
Study: NCT00615875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
Study: NCT01941173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT03344211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study: NCT04087811

Intervention type: DEVICE
Intervention: Superion® Indirect Decompression System (IDS)
Description: Superion® Indirect Decompression System (IDS) (Superion® implant)
Study: NCT00652769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial or Endoscopic Ultrasound
Description: Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy
Description: Investigations will be determined by the multi-disciplinary team responsible for the patient
Study: NCT06242769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride Toothpaste (SnF)
Description: test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stannous Fluoride Toothpaste (SnF)
Description: test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Fluoride Toothpaste (CDC)
Description: negative control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Fluoride Toothpaste (CDC)
Description: negative control
Study: NCT00218608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
Study: NCT04243265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPFL reconstruction with fascia lata allograft
Description: Reconstruction of MPFL using a fascia lata allograft. The rationale for this technique is to stabilize the patella and limit medium to long-term patellofemoral arthritic degeneration by restoring the MPFL in the most anatomical way possible, not using a tubular graft but an aponeurosis with biomechanical characteristics similar to the native MPFL. The MPFL reconstruction can be used alone or in association with the realignment of the extensor apparatus by transposition of the anterior tibial tuberosity, managing to correct most of the recurrent patellofemoral instabilities. Only in very serious particular cases is it necessary to perform more invasive additional procedures with a more uncertain clinical result (such as Trocleoplasty).
Study: NCT02847429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01720576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)
Study: NCT02690012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Magnesium Oxide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Citrate
Description: Magnesium Citrate
Study: NCT01720576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo